GleamWall
中文EN

FEMY FEMASYS INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1339005 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.2%
TTM net income YoY38.7%
TTM EPS YoY175.8%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—

Margins

Gross margin59.9%
Operating margin-929.9%
Net margin-614.7%
FCF margin-877.5%
EBITDA margin-913.3%

Returns

ROE-76.9%
ROA-47.3%
ROIC (approx.)-935.4%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets23.0%
Debt / equity0.00x
Current ratio8.67x
Interest coverage-18.91x

Cash quality & payout

Operating cash flow / net income1.41x
Accruals ratio19.2%
Payout ratio—
Capex / revenue12.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$404,597$331,827$424,889$813,387$729,394$409,268$341,264$581,576
Cost of revenue$187,496$142,436$158,606$303,125$293,838$158,171$117,266$192,407
Gross profit$217,101$189,391$266,283$510,262$435,556$251,097$223,998$389,169
R&D expense$1.94M$1.95M$1.31M$1.81M$1.38M$1.41M$2.97M$2.17M
SG&A expense$1.70M$1.93M$1.78M$1.83M$1.48M$1.62M$1.72M$1.68M
Operating income-$4.45M-$5.07M-$4.22M-$4.62M-$3.65M-$3.85M-$5.46M-$4.72M
Interest expense$200,415$186,050$176,607$408,097$532,073$491,500$459,449$440,422
Pretax income-$4.56M-$4.47M$846,100-$3.94M-$4.19M-$4.59M-$5.90M-$5.11M
Income tax$0$865$0$5,485$0$0-$4,188$10,194
Net income-$4.56M-$4.47M$846,100-$3.95M-$4.19M-$4.59M-$5.90M-$5.12M
EBITDA-$4.37M-$4.98M-$4.14M-$4.54M-$3.57M-$3.77M-$5.38M-$4.64M
EPS (basic)-0.53-1.330.00—-2.05-3.18-0.23—
EPS (diluted)-0.53-1.330.00—-2.05-3.18-0.23—
Weighted avg. shares (diluted)8.66M3.36M78.10M—2.05M1.44M25.15M—
Balance sheet
Cash & equivalents$23.91M$1.44M$5.39M$9.27M$4.57M$3.22M$3.82M$3.45M
Receivables$233,778$151,049$172,264$616,600$572,199$254,584$233,598$488,373
Inventory$6.17M$6.19M$6.11M$5.74M$5.78M$5.23M$3.86M$3.05M
Current assets$31.21M$8.33M$12.34M$16.46M$12.25M$9.75M$9.13M$8.02M
PP&E, net$1.88M$1.86M$1.92M$1.90M$1.75M$1.60M$1.58M$1.60M
Intangibles$99,902$115,499$124,252$134,914$130,041$55,638$58,747$65,918
Total assets$35.09M$12.29M$16.50M$20.72M$16.29M$13.78M$13.28M$12.45M
Current liabilities$3.60M$3.89M$3.16M$3.64M$10.54M$10.96M$9.84M$8.58M
Total liabilities$8.06M$8.26M$9.21M$14.85M$11.73M$12.27M$11.28M$10.14M
Shareholders' equity$27.03M$4.03M$7.29M$5.87M$4.56M$1.51M$2.00M$2.30M
Shares outstanding8.66M3.02M60.39M2.98M47.30M32.58M27.09M23.36M
Cash flow statement
Operating cash flow-$4.82M-$3.94M-$4.14M-$4.19M-$5.39M-$4.35M-$4.77M-$5.07M
Capital expenditure$17,510$9,402$79,138$139,840$194,333$94,229$96,605$106,792
Free cash flow-$4.84M-$3.95M-$4.22M-$4.33M-$5.58M-$4.45M-$4.86M-$5.18M
Investing cash flow-$21,015-$22,179-$79,138-$196,715-$239,816-$96,962-$96,605-$110,613
Financing cash flow$27.31M$15,329$342,334$9.08M$6.98M$3.85M$5.23M$1.03M
Depreciation & amortization$77,091$82,811$82,270$85,199$85,697$86,285$84,853$82,174
Stock-based compensation$190,216$210,820$151,608$66,423$174,514$181,971$367,237$134,143
Share buybacks——————$161,761$30,093

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.